DE69930758T2 - Verwendung von daptomycin - Google Patents

Verwendung von daptomycin Download PDF

Info

Publication number
DE69930758T2
DE69930758T2 DE69930758T DE69930758T DE69930758T2 DE 69930758 T2 DE69930758 T2 DE 69930758T2 DE 69930758 T DE69930758 T DE 69930758T DE 69930758 T DE69930758 T DE 69930758T DE 69930758 T2 DE69930758 T2 DE 69930758T2
Authority
DE
Germany
Prior art keywords
use according
dose
daptomycin
hours
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69930758T
Other languages
German (de)
English (en)
Other versions
DE69930758D1 (de
DE122006000049I1 (de
Inventor
B. Frederick Concord OLESON
P. Francis Lincoln TALLY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cubist Pharmaceuticals LLC
Original Assignee
Cubist Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26798675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69930758(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cubist Pharmaceuticals LLC filed Critical Cubist Pharmaceuticals LLC
Publication of DE69930758D1 publication Critical patent/DE69930758D1/de
Application granted granted Critical
Publication of DE69930758T2 publication Critical patent/DE69930758T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE69930758T 1998-09-25 1999-09-24 Verwendung von daptomycin Expired - Lifetime DE69930758T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10182898P 1998-09-25 1998-09-25
US101828P 1998-09-25
US12575099P 1999-03-24 1999-03-24
US125750P 1999-03-24
PCT/US1999/022366 WO2000018419A2 (en) 1998-09-25 1999-09-24 Methods for administration of antibiotics

Publications (2)

Publication Number Publication Date
DE69930758D1 DE69930758D1 (de) 2006-05-18
DE69930758T2 true DE69930758T2 (de) 2007-04-26

Family

ID=26798675

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69930758T Expired - Lifetime DE69930758T2 (de) 1998-09-25 1999-09-24 Verwendung von daptomycin
DE1999630758 Pending DE122006000049I1 (de) 1998-09-25 1999-09-24 Verwendung von Daptomycin
DE200612000049 Active DE122006000049I2 (de) 1998-09-25 1999-09-24 Verwendung von Daptomycin

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE1999630758 Pending DE122006000049I1 (de) 1998-09-25 1999-09-24 Verwendung von Daptomycin
DE200612000049 Active DE122006000049I2 (de) 1998-09-25 1999-09-24 Verwendung von Daptomycin

Country Status (26)

Country Link
US (2) US6468967B1 (cg-RX-API-DMAC7.html)
EP (2) EP1674107B8 (cg-RX-API-DMAC7.html)
JP (4) JP4184607B2 (cg-RX-API-DMAC7.html)
KR (2) KR20010075327A (cg-RX-API-DMAC7.html)
CN (2) CN1150029C (cg-RX-API-DMAC7.html)
AT (1) ATE322280T1 (cg-RX-API-DMAC7.html)
AU (1) AU764348B2 (cg-RX-API-DMAC7.html)
BR (1) BR9914051A (cg-RX-API-DMAC7.html)
CA (1) CA2344318C (cg-RX-API-DMAC7.html)
CY (3) CY1105556T1 (cg-RX-API-DMAC7.html)
DE (3) DE69930758T2 (cg-RX-API-DMAC7.html)
DK (2) DK1674107T3 (cg-RX-API-DMAC7.html)
ES (2) ES2259845T3 (cg-RX-API-DMAC7.html)
HK (1) HK1040363B (cg-RX-API-DMAC7.html)
HU (1) HU230656B1 (cg-RX-API-DMAC7.html)
IS (2) IS5890A (cg-RX-API-DMAC7.html)
LU (1) LU91254I2 (cg-RX-API-DMAC7.html)
NL (1) NL300232I2 (cg-RX-API-DMAC7.html)
NO (1) NO20011454L (cg-RX-API-DMAC7.html)
NZ (1) NZ510690A (cg-RX-API-DMAC7.html)
PL (2) PL206091B1 (cg-RX-API-DMAC7.html)
PT (2) PT1115417E (cg-RX-API-DMAC7.html)
RU (1) RU2363489C9 (cg-RX-API-DMAC7.html)
SI (2) SI1674107T1 (cg-RX-API-DMAC7.html)
TR (1) TR200100841T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000018419A2 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018419A2 (en) 1998-09-25 2000-04-06 Cubist Pharmaceuticals, Inc. Methods for administration of antibiotics
CA2393907A1 (en) 1999-12-15 2001-06-21 Cubist Pharmaceuticals Inc. Novel lipopeptides as antibacterial agents
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
WO2002059145A1 (en) * 2000-12-18 2002-08-01 Cubist Pharmaceuticals, Inc. Methods for preparing purified lipopeptides
US20060014674A1 (en) 2000-12-18 2006-01-19 Dennis Keith Methods for preparing purified lipopeptides
US20030045678A1 (en) 2000-12-18 2003-03-06 Dennis Keith Methods for preparing purified lipopeptides
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
WO2004017925A2 (en) * 2002-08-23 2004-03-04 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050277581A1 (en) * 2002-11-18 2005-12-15 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
EP2018864A1 (en) * 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
MX2010009628A (es) * 2008-03-04 2010-09-28 Elan Pharma Int Ltd Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos.
EP3632459A1 (en) 2008-07-17 2020-04-08 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
US8629139B2 (en) 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
US8809263B2 (en) * 2008-10-24 2014-08-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Anti-infective hydroxy-phenyl-benzoates and methods of use
CN102325787B (zh) 2008-12-22 2014-05-28 丘比斯特药物股份有限公司 治疗革兰氏阳性感染的新的抗菌剂
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CA2767614C (en) * 2009-07-13 2019-01-15 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
US8450300B2 (en) * 2009-07-13 2013-05-28 Cempra Pharmaceuticals Inc. Fusidic acid dosing regimens for treatment of bacterial infections
CN102724983A (zh) 2009-09-04 2012-10-10 Mpex医药有限公司 雾化左氧氟沙星治疗囊性纤维化的用途
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
US8247394B2 (en) 2010-06-02 2012-08-21 Cempra Pharmaceuticals Inc. Methods of treating urethritis and related infections using fusidic acid
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
US8461188B2 (en) 2011-10-20 2013-06-11 Trius Therapeutics, Inc. Therapeutic combination of daptomycin and protein synthesis inhibitor antibiotic, and methods of use
US8940897B2 (en) 2012-03-30 2015-01-27 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
EP4066849B1 (en) * 2012-09-11 2025-03-05 Hospira Australia Pty Ltd Daptomycin formulations and uses thereof
CN103006562B (zh) * 2013-01-21 2014-09-17 西南大学 达托霉素醇质体制剂
WO2014152332A1 (en) 2013-03-15 2014-09-25 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides
CA3021745A1 (en) * 2016-05-13 2017-11-16 Spero Potentiator, Inc. Potentiation of antibiotic activity by a novel cationic peptide, spr741
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32333E (en) 1978-10-16 1987-01-20 Eli Lilly And Company A-21978 Antibiotics and process for their production
USRE32455E (en) 1978-10-16 1987-07-07 Eli Lilly And Company A-21978 antibiotics and process for their production
US4524135A (en) 1982-05-21 1985-06-18 Eli Lilly And Company A-21978C cyclic peptides
USRE32310E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
USRE32311E (en) 1982-05-21 1986-12-16 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
US4482487A (en) 1982-05-21 1984-11-13 Eli Lilly And Company A-21978C cyclic peptides
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
US4800157A (en) 1985-09-09 1989-01-24 Eli Lilly And Company Process for producing the A-21978C antibiotics
ZA883887B (en) 1987-06-10 1990-02-28 Lilly Co Eli Chromatographic purification process
US4874843A (en) 1987-12-03 1989-10-17 Eli Lilly And Company Chromatographic purification process
NZ232763A (en) * 1989-03-06 1991-09-25 Lilly Co Eli Parenteral formulation comprising daptomycin with a buffer to maintain ph between 6.0 and 8.0
FR2755857B1 (fr) 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
FR2772272B1 (fr) * 1997-12-16 2000-01-14 Rhone Poulenc Rorer Sa Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
WO2000018419A2 (en) 1998-09-25 2000-04-06 Cubist Pharmaceuticals, Inc. Methods for administration of antibiotics
US9393093B2 (en) 2008-02-18 2016-07-19 Covidien Lp Clip for implant deployment device

Also Published As

Publication number Publication date
EP1674107B1 (en) 2016-08-24
EP1115417B1 (en) 2006-04-05
HUP0103874A3 (en) 2002-09-30
CA2344318C (en) 2006-07-04
CY2006003I2 (el) 2009-11-04
HUP0103874A2 (hu) 2002-02-28
HK1040363B (en) 2007-01-26
PL206091B1 (pl) 2010-06-30
EP1674107A8 (en) 2006-10-04
RU2363489C9 (ru) 2010-03-20
PL203689B1 (pl) 2009-11-30
EP1674107A3 (en) 2012-06-20
RU2004106569A (ru) 2005-08-10
CY1118334T1 (el) 2017-06-28
EP1115417A2 (en) 2001-07-18
LU91254I2 (fr) 2006-08-28
NZ510690A (en) 2002-10-25
JP2006335773A (ja) 2006-12-14
EP1674107A2 (en) 2006-06-28
ES2603086T3 (es) 2017-02-23
DE69930758D1 (de) 2006-05-18
WO2000018419A2 (en) 2000-04-06
WO2000018419A3 (en) 2000-07-06
HK1040363A1 (en) 2002-06-07
CY2006003I1 (el) 2009-11-04
ES2259845T3 (es) 2006-10-16
SI1115417T1 (sl) 2006-08-31
RU2363489C2 (ru) 2009-08-10
EP1674107B8 (en) 2017-01-25
HU230656B1 (hu) 2017-06-28
PT1115417E (pt) 2006-07-31
PT1674107T (pt) 2016-12-07
NL300232I1 (nl) 2006-09-01
NL300232I2 (nl) 2007-01-02
US6852689B2 (en) 2005-02-08
DE122006000049I1 (de) 2007-01-04
US20020142948A1 (en) 2002-10-03
SI1674107T1 (sl) 2017-01-31
IS8807A (is) 2009-03-10
US6468967B1 (en) 2002-10-22
CN1348382A (zh) 2002-05-08
AU764348B2 (en) 2003-08-14
KR20100051735A (ko) 2010-05-17
NO20011454L (no) 2001-05-25
DK1674107T3 (en) 2016-12-19
CY1105556T1 (el) 2010-07-28
BR9914051A (pt) 2001-06-19
CN1150029C (zh) 2004-05-19
NO20011454D0 (no) 2001-03-22
DK1115417T3 (da) 2006-07-31
CA2344318A1 (en) 2000-04-06
ATE322280T1 (de) 2006-04-15
IS5890A (is) 2001-03-14
JP4184607B2 (ja) 2008-11-19
CN1530136A (zh) 2004-09-22
TR200100841T2 (tr) 2002-01-21
KR20010075327A (ko) 2001-08-09
PL348328A1 (en) 2002-05-20
AU6268799A (en) 2000-04-17
JP2003321389A (ja) 2003-11-11
JP2004339238A (ja) 2004-12-02
DE122006000049I2 (de) 2007-11-08
JP2002525335A (ja) 2002-08-13

Similar Documents

Publication Publication Date Title
DE69930758T2 (de) Verwendung von daptomycin
DE69629691T2 (de) Verfahren zur kontrolle von antibiotikaresistenten grampositiven bakterien und behandlung von infektionen
DE69833377T2 (de) Pharmazeutische zusammensetzungen enthaltend lysostaphin allein oder in kombination mit einem antibiotikum zur behandlung von staphylokokkeninfektionen
DE602004013035T2 (de) Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung
DE69323568T2 (de) Antimikrobielle Zusammensetzungen und pharmazeutische Präparate hiervon
DE3916417C2 (cg-RX-API-DMAC7.html)
DE2608079A1 (de) Arzneipraeparat in form eines trockenpraeparats zur herstellung von injektionen
DE69115102T2 (de) Stabilisator für eine 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide enthaltende Zusammensetzung und Stabilisierungsverfahren.
DE60114567T2 (de) Selektive acylierung von a82846-glycopeptid-analoge
EP1480646A1 (de) Antiinfektiva und/oder immunmodulatoren zur präventiven therapie nach akutem schlaganfall
JP2003246726A (ja) 抗菌組成物
DE60106463T2 (de) Zusammensetzungen aus dalfopristin und quinupristin mit cefpirom
RU2232592C2 (ru) Способ лечения бактериальной инфекции
HK1094672A (en) Use of daptomycin
DE2650608A1 (de) Arzneipraeparat zur behandlung von mastitis bei milchvieh
CZ20011014A3 (cs) Farmaceutické přípravky obsahující lipoproteinová antibiotika
WO2008131746A2 (de) Mittel zur präventiven antiinfektiven behandlung eines patienten

Legal Events

Date Code Title Description
V448 Application of spc

Free format text: PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001, EU/1/05/328/002; 20060119

Spc suppl protection certif: 12 2006 000 049

Filing date: 20060915

8363 Opposition against the patent
V484 Delivery of the decision of grant

Free format text: PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001, EU/1/05/328/002; 20060119

Spc suppl protection certif: 12 2006 000 049

Filing date: 20060915

V457 Spc granted

Free format text: PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001, EU/1/05/328/002; 20060119

Spc suppl protection certif: 12 2006 000 049

Filing date: 20060915